In breast cancer, a synthetic inhibitor of GLUT1 known as WZB117, was demonstrated to radio-sensitize cancer by increasing the level of intracellular ROS, thereby inhibiting tumor growth (Zhao et al., 2016). Here, SLC2A1 is linked to breast carcinoma.